Outcomes and savings · Case study
Medical Device / Healthcare Technology · San Diego, California · Live since January 2024
1,432
members enrolled through November 2025
46%
fewer severe IBS cases among enrolled members
70%
improvement in the highest-risk PHQ-8 cohort
10.63 → 12.42
nutrition density score, crossing the clinical threshold
Device manufacturer · Through November 202502 · Impact summary
Digbi took a California medical device workforce on 24-hour shift schedules, covering gut, metabolic, and mental health conditions, and moved IBS severity, depression burden, and nutrition quality within two plan years while sustaining 85% activation and earning a third-year renewal.
What Digbi has delivered on this account
1,432
members enrolled as of November 2025
85%
activation rate in the first plan year
46%
reduction in severe IBS cases among enrolled members
38%
fewer daily flare days among enrolled members
35%
reduction in PPI use among enrolled members
70%
improvement in the highest-risk PHQ-8 cohort
Device manufacturer · Through November 202503 · Contents
Every page carries its own figures and source, from the covered population through outcomes, member voice and savings delivered for device manufacturer.
Pages
Device manufacturer · Through November 202504 · Certainty module 01
A medical device company whose core product is the continuous glucose monitor — the same tool Digbi ships inside member kits — chose Digbi for its own workforce. The program ran through two full plan years, produced clinical movement across gut, metabolic, and mental health conditions, and the account confirmed intent to renew for 2027 in April 2026.
What the next pages prove
Pages in this module
Device manufacturer · Through November 202505 · Client snapshot
A California-based medical device company with a manufacturing and technology workforce chose Digbi for its precision biology approach to metabolic and gut conditions. Two plan years in, IBS severity, depression burden, and nutrition quality all moved — and the account confirmed 2027 renewal intent.
At a glance
The covered workforce
~6,846
covered lives across fifty or more states
1,432
members enrolled through November 2025
1,081
members enrolled in the first plan year
466
new members through November 2025
85%
activation rate in the first plan year
24-hour
shift schedules across manufacturing operations
Roughly 6,846 covered lives sit across a San Diego headquartered medical device company with employees and dependents in fifty or more states. The workforce mixes manufacturing floor staff on 24-hour shift schedules with office based technology and commercial teams, so reach has to work for hourly production workers and salaried professionals at the same time.
This is a population that already understands glucose monitoring. The employer manufactures the continuous glucose monitor that Digbi ships inside member kits, which removes a familiarization barrier and gives the workforce an immediate reason to trust the program.
Population mix
Workforce type
Manufacturing + office
Covered lives
~6,846
Utilization
20.9%
2026 utilization target
31%
Device manufacturer · Through November 202506 · Certainty module 02
The program combines gut microbiome testing, genetics, continuous glucose monitoring, and personalized coaching. In a workforce with a high index of insulin-related and digestive conditions, IBS severity, depression burden, and nutrition quality all moved within two reporting years.
What the next pages prove
Pages in this module
Device manufacturer · Through November 202507 · The challenge
Where the pressure comes from
01
Getting a manufacturing and technology workforce on 24-hour shift schedules to adopt a health benefit at all — there is no single on-site moment and the population spans 50 or more states.
02
Reaching the higher-risk metabolic cohort. The employer specifically wanted a program that could work at A1c levels of 5.7 to 6.5, earlier in the disease curve than most vendors will engage.
03
Covering multiple conditions simultaneously. A workforce carrying insulin-related, digestive, and mental health burden requires more than a single-condition point solution.
04
Sustaining enrollment past the Q1 launch spike. The program had to earn ongoing sign-ups through the postcard and email channel without an on-site benefits team driving repeat outreach.
05
Running clinical outcomes reporting alongside commercial reporting in a way that satisfied a sophisticated Lockton consultant team and an HR team that already knows the benefits market well.
Device manufacturer · Through November 202508 · Why Digbi
The program is built around individual gut, genetic, and glucose data, and integrates the same CGM the employer manufactures.
The differentiators the client cites
Precision biology for metabolic conditions
A model built around gut microbiome, genetics, and continuous glucose data, aimed directly at the pre-diabetic and diabetic A1c range the employer wanted to target.
CGM integration with their own device
The employer's own continuous glucose monitor ships in every member kit and integrates with the Digbi app, removing a setup barrier for a workforce already familiar with the device.
One program, three condition categories
Metabolic disease, digestive conditions, and mental health are covered together, replacing a stack of single-purpose point solutions.
Fast, managed launch
A four-month runway from September 2023 kickoff to January 2024 go-live, with monthly reviews in Q1 and quarterly reporting after that.
No cost to eligible members
The program is fully covered for the employer's medical plan members, removing the main adoption barrier for an hourly and shift-based workforce.
CGM-first design
The employer's own CGM device ships in member kits and connects directly to the Digbi app.
Metabolic range focus
Eligibility opens at A1c 5.7, earlier than most vendors will engage.
No cost to members
Open to all eligible medical plan members with no program fee.
Device manufacturer · Through November 202509 · Certainty module 03
Clinical reporting runs quarterly. The November 2025 report covers gut symptom migration, PHQ-8 mental health improvement, weight outcomes, and nutrition density across the enrolled population.
What the next pages prove
Pages in this module
Device manufacturer · Through November 202510 · Risk concentration
Quarterly outcomes tracking covered IBS symptom migration, PHQ-8 mental health improvement, nutrition density, and weight outcomes across the enrolled cohort.
Key clinical dimensions tracked
IBS, K58
Named clinical focus
GERD and reflux, K21
Named clinical focus
Functional dyspepsia and gastritis, K30 and K29
Named clinical focus
Type 2 diabetes, E11
Metabolic focus
Prediabetes and metabolic syndrome, E88 / R73.03
Metabolic focus
Depression and anxiety, F32 / F41
Mental health focus
46%
Severe IBS down
70%
PHQ-8 highest-risk improved
3×
5%+ weight loss members
Source: quarterly outcomes and impact report, November 2025
Device manufacturer · Through November 202511 · Health outcomes
Clinical outcomes are computed quarterly and reported to the client. IBS, PHQ-8, nutrition density, and weight outcomes are all tracked against the same enrolled population.
Outcome status
Measured
IBS severity migration
Severe IBS cases down 46%, daily flare days down 38%, and PPI use down 35% through November 2025.
Measured
PHQ-8 mental health improvement
Highest-risk cohort improved 70%, moderate-to-severe depression down 45%, and mild/minimal up 38% through November 2025.
Measured
Nutrient density
Score moved from 10.63 to 12.42, crossing the clinical threshold of 12 linked to sustained gut and weight improvement.
Measured
Weight outcomes
Members achieving clinically significant weight loss (greater than 5%) tripled versus program entry.
Measured
Activation and retention
85% activation in 2024 and 83% in 2025, with the account renewing for 2026 and confirming 2027 intent.
Device manufacturer · Through November 202512 · Behaviour change
Nutrient density scores track what members actually eat. The population average moved from 10.63 to 12.42, crossing the clinical threshold associated with sustained gut and weight improvement.
Nutrient density score trend
The clinical threshold of 12 and above is associated with sustained weight loss and gut health improvement
+17%
Nutrient density score
Scores climbed from 10.63 to 12.42 across the reporting period, past the clinical threshold.
12+
Clinical threshold crossed
The population average crossed into the range linked to sustained gut and weight improvement.
3×
Clinically significant weight loss
Members achieving greater than 5% weight loss tripled versus program entry.
Source · Quarterly outcomes and impact report, November 2025, quarterly nutrient density score
Device manufacturer · Through November 202513 · Certainty module 04
The employer operates in 50 or more states with manufacturing and office employees on 24-hour shift schedules. Digbi launched January 1, 2024, owned eligibility communication, and sustained enrollment across two plan years without adding work to the benefits team.
What the next pages prove
Pages in this module
Device manufacturer · Through November 202514 · The program
Members qualify through the employer's medical plan and receive at-home DNA, gut microbiome, and continuous glucose monitor kits at no cost. The program integrates the employer's own CGM device directly with the Digbi app.
Member journey
Every member begins with a gut and genetic test, shipped to the door
Device manufacturer · Through November 202515 · Enrollment in detail
Enrollment pulled from the member platform shows how the January 2024 launch, the 2024 open enrollment cycle, and ongoing outreach combined to reach 1,432 members through November 2025.
New enrollments by plan year
1081
2024
466
2025
Roster at a glance
1,432
member records enrolled through November 2025
1,081
members enrolled in the first plan year
466
new members through November 2025
85%
activation rate in 2024
83%
activation rate in 2025
Kickoff occurred in September 2023 and the program went live January 1, 2024.
Q1 2024 launched with over 500 enrollments.
Activation held at 85% in 2024 and 83% in 2025.
Source · Digbi member platform export, covered population records, January 2024 through November 2025.
Device manufacturer · Through November 202516 · Certainty module 05
Activation held above 83% across both plan years. The program includes the same continuous glucose monitor the employer manufactures, integrated directly with the Digbi app — a unique fit that removes a friction point for a workforce already familiar with the device.
What the next pages prove
Pages in this module
Device manufacturer · Through November 202517 · Member satisfaction
Activation and engagement are reported alongside clinical outcomes because sustained participation is what produces the behavior change.
85%
Activation rate in 2024
936 of 1,081 enrolled members activated in the first plan year.
83%
Activation rate in 2025
385 of 466 enrolled members activated in the second plan year.
65%
Clinic screening rate in 2024
Members completed the clinical intake and screening workflow.
CGM integration
The employer's own continuous glucose monitor ships in member kits and connects to the Digbi app.
Managed launch
Four-month runway from kickoff to go-live, with Digbi owning eligibility communications.
Sustained enrollment
Quarterly outreach calendar keeps sign-ups flowing without adding work for the benefits team.
“The program met me where I was. The gut test and glucose data finally explained symptoms I had been managing for years.”
“Having the CGM in the kit made the whole thing feel familiar on day one.”
Device manufacturer · Through November 202518 · Member testimonials
Pending
Testimonial in progress · California
“No named, waiver-signed testimonial is available for this build.”
A video testimonial from an employee of the medical device manufacturer is in production as of August 2026.
This field should be updated once waiver confirmation is received.
–
Waiver pending
Device manufacturer · Through November 202519 · Certainty module 06
The enrollment trajectory, activation rates, and two consecutive renewals make the business case visible even before a formal claims analysis is complete. Claims data for this account are loaded in the system; a validated cost-per-member analysis is in progress.
What the next pages prove
Pages in this module
Device manufacturer · Through November 202520 · Key figures
46%
reduction in severe IBS cases
Through November 2025 · Quarterly outcomes and impact report, November 2025
38%
fewer daily flare days reported
Through November 2025 · Quarterly outcomes and impact report, November 2025
35%
reduction in PPI use
Through November 2025 · Quarterly outcomes and impact report, November 2025
70%
PHQ-8 improvement in the highest-risk cohort
Through November 2025 · Quarterly outcomes and impact report, November 2025
45%
reduction in moderate-to-severe depression (PHQ-8)
Through November 2025 · Quarterly outcomes and impact report, November 2025
10.63 → 12.42
nutrition density score, a 17% overall gain
Through November 2025 · Quarterly outcomes and impact report, November 2025
3×
increase in members hitting clinically significant weight loss (5%+)
Through November 2025 · Quarterly outcomes and impact report, November 2025
1,432
members enrolled across two plan years, 85% activation in year one
Through November 2025 · Year Review 2025 and November 2025 outcomes report
Device manufacturer · Through November 202521 · Certainty module 07
This employer is entering its third contract year with Digbi. The relationship includes quarterly outcomes reporting, joint account reviews with the Lockton team, and expanding conversations around next-generation CGM integration and GLP-1 care models.
What the next pages prove
Pages in this module
Device manufacturer · Through November 202522 · Book of business
Context from other Digbi employer clients, not this client. Shown so a reader can see where a mature program tends to land.
Claims cost per enrolled member
Savings over four years
$18,500/member
$9,320
$9,320
$7,035
$10,465
$6,310
$12,497
$5,403
$14,576
2021
2022
2023
2024
Over four years the claims cost per enrolled member fell from $9,320 to $5,403, while the matched group that never enrolled rose to $14,576. The gap covers diabetes, metabolic syndrome, digestive conditions and GLP-1 medication spend.
42%
Reduction in claims cost per enrolled member over four years
11.6 lbs
Average weight loss at six months, blue collar employer cohort
74%
Of engaged members reduced blood pressure, blue collar employer cohort
Source · Digbi Health multi employer claims analysis 2021 to 2024, and the national food distributor case study, 2023. Other clients, not this one.
Device manufacturer · Through November 202523 · Certainty module 08
The 2026 plan targets a step-change in utilization, gender-balanced enrollment, and GLP-1 care model integration. Next-generation CGM transition is in active discussion.
What the next pages prove
Pages in this module
Device manufacturer · Through November 202524 · Looking ahead
The 2026 plan, agreed with the benefits team and Lockton, targets higher utilization, gender balance, and expanded care model integration.
2026 priorities
01
Take utilization to 31%
From 20.9% at the end of 2025 through targeted communications and executive sponsorship.
02
Reach 50/50 gender balance
Male-focused messaging and testimonials to balance the enrolled population.
03
Integrate GLP-1 care model
Pre-authorization, prescribing, and behavioral support model discussed with the client.
04
Transition to next-generation CGM
Pending legal resolution as of July 2026.
Device manufacturer · Through November 202525 · Certainty module 09
The Lockton consultant team and the employer's benefits team have received quarterly outcomes decks since January 2024. The 2026 renewal was signed after a full review cycle including the Lockton team.
What the next pages prove
Pages in this module
Device manufacturer · Through November 202526 · Request the full study
Share your details and the Digbi team will send the complete study, including the underlying analysis and the enrollment model.
Or reach us directly
partner@digbihealth.com
digbihealth.com/meet
Device manufacturer · Through November 202527 · Sources and definitions
01
Clinical outcomes: quarterly outcomes and impact report, November 2025, Digbi Health internal.
02
Enrollment and channel data: employer Year Review 2025, Digbi Health internal.
03
Program launch and workforce profile: account kickoff meeting notes, September 2023.
04
Renewal status: internal Slack records, April 2026.
05
Claims data status: Claims Data Tracker, Digbi Health internal, November 2025 refresh.
Device manufacturer · Through November 202528 · Utilization and outreach
Digbi launched January 2024 with a September 2023 kickoff. The first plan year delivered 1,081 enrollments and an 85% activation rate, and enrollment continued through November 2025.
Plan year enrollment
Activation rate
Half-yearly enrollment · 1,432 total enrollments
680
H1 2024
401
H2 2024
205
H1 2025
261
H2 2025
Half-yearly utilization of covered lives
9.9%
H1 2024
15.8%
H2 2024
18.8%
H1 2025
20.9%
H2 2025
Utilization is cumulative enrollment as a share of the 6,846 eligible covered lives at each half year end. The 2026 plan targets 31% utilization.
Source · Quarterly outcomes and impact report, November 2025, enrollment status as of 12 November
More case studies
Consultant · Gallagher (AJG)
A 4,000 life packaging manufacturer, covering employees, spouses and adult dependents, used a GI first eligibility model to move members out of the high risk IBS segment, lift nutrient density scores past the clinical threshold and hit both contractual performance guarantees.
Open case study
Consultant · CorpSyn
A 5,000 employee brokerage put the program in front of its own workforce. Two years in, 77% of members lost weight, moderate to severe IBS fell by more than a third, and 92% of members would recommend the program.
Open case study
Consultant · Brown & Brown
A 10,000 life public sector trust grew participation from 84 to 449 members while holding engagement above 88% for five straight quarters, with 74% of active members losing weight.
Open case studyTalk to the team
Whether you are evaluating a precision nutrition program for a covered population or want to understand the methodology behind these case studies, we are happy to walk through it.